Clinical outcomes in patients evaluated for efficacy: duration of response to prior therapy and to pembrolizumab
| . | Prior lines of therapy . | Duration of response to prior therapy, mo (type of response) . | Duration of response to pembrolizumab, mo . |
|---|---|---|---|
| Complete responders | |||
| Patient 2 (SCT ineligible) | ACVBP | 2 (PR) | 20.5* (response ongoing) |
| R-DHAX | 3 (PR) | — | |
| R-CHOP | — (SD) | — | |
| BV | — (PD) | — | |
| Patient 7 (prior autologous SCT) | R-CHOP | — (SD) | 2.4 (response ongoing) |
| R-ACVB | — (PR) | — | |
| MTX | — (PR) | — | |
| R-IE | — (PR) | — | |
| AraC | — (PD) | — | |
| R-DHAP | — (PR) | — | |
| Partial responders | |||
| Patient 1 (prior autologous SCT) | R-VACOP-B | — (SD) | 22.4 (response ongoing) |
| R-DHAP | 1 (PR) | — | |
| CCNU-EAM | — (SD) | — | |
| DA-EPOCH | — (PD) | — | |
| Patient 4 (SCT ineligible) | BV | — (PD) | — |
| R-CHOP | 3 (PR) | 6.9 (disease progression) | |
| R-DAC | — (SD) | — | |
| Patient 3 (SCT ineligible) | IP-NVB | — (SD) | — |
| R-EPOCH | — (SD) | 6.5 (response ongoing) | |
| Patient 8 (prior autologous SCT) | R-DHAP | — (PD) | — |
| CHO-MTX | 1 (PR) | 4.6 (response ongoing) | |
| IE | 5 (CR) | — | |
| Patient 5 (SCT ineligible) | BEAM | — (PD) | — |
| R-EPOCH | 1 (PR) | 4.0 (response ongoing) | |
| R-DHAP | — (PD) | — |
| . | Prior lines of therapy . | Duration of response to prior therapy, mo (type of response) . | Duration of response to pembrolizumab, mo . |
|---|---|---|---|
| Complete responders | |||
| Patient 2 (SCT ineligible) | ACVBP | 2 (PR) | 20.5* (response ongoing) |
| R-DHAX | 3 (PR) | — | |
| R-CHOP | — (SD) | — | |
| BV | — (PD) | — | |
| Patient 7 (prior autologous SCT) | R-CHOP | — (SD) | 2.4 (response ongoing) |
| R-ACVB | — (PR) | — | |
| MTX | — (PR) | — | |
| R-IE | — (PR) | — | |
| AraC | — (PD) | — | |
| R-DHAP | — (PR) | — | |
| Partial responders | |||
| Patient 1 (prior autologous SCT) | R-VACOP-B | — (SD) | 22.4 (response ongoing) |
| R-DHAP | 1 (PR) | — | |
| CCNU-EAM | — (SD) | — | |
| DA-EPOCH | — (PD) | — | |
| Patient 4 (SCT ineligible) | BV | — (PD) | — |
| R-CHOP | 3 (PR) | 6.9 (disease progression) | |
| R-DAC | — (SD) | — | |
| Patient 3 (SCT ineligible) | IP-NVB | — (SD) | — |
| R-EPOCH | — (SD) | 6.5 (response ongoing) | |
| Patient 8 (prior autologous SCT) | R-DHAP | — (PD) | — |
| CHO-MTX | 1 (PR) | 4.6 (response ongoing) | |
| IE | 5 (CR) | — | |
| Patient 5 (SCT ineligible) | BEAM | — (PD) | — |
| R-EPOCH | 1 (PR) | 4.0 (response ongoing) | |
| R-DHAP | — (PD) | — |
Patient numbers refer to Figure 1.
ACVBP, bleomycin, cyclophosphamide, doxorubicin, prednisone, and vindesine; AraC, cytarabine; BEAM, melphalan, carmustine, cytarabine, and etoposide; BV, brentuximab vedotin; CCNU-EAM, cytarabine, etoposide, lomustine, and melphalan; CHO-MTX, doxorubicin, cyclophosphamide, vincristine sulfate, methotrexate, etoposide, and ifosfamide; DA-EPOCH, cyclophosphamide, doxorubicin, etoposide, prednisone, and vincristine sulfate; IE, etoposide and ifosfamide; IP-NVB, ifosfamide, methylprednisolone, and vinorelbine tartrate; MTX, methotrexate; PD, progressive disease; PR, partial response; R-IE, rituximab, etoposide, and ifosfamide; R-AVCB, rituximab, doxorubicin, vindesine, bleomycin, and cyclophosphamide; R-CHOP, cyclophosphamide, doxorubicin, prednisone, rituximab, and vincristine sulfate; R-DAC, carboplatin, cytarabine, dexamethasone, and rituximab; R-DHAP, rituximab, cytarabine, cisplatin, and dexamethasone; R-DHAX, cytarabine, dexamethasone, oxaliplatin, and rituximab; R-EPOCH, cyclophosphamide, doxorubicin, etoposide, prednisone, rituximab, and vincristine sulfate; R-VACOP-B, etoposide, leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin.
Patient initially presented with partial response, and the time shown represents the total duration of response since the date partial response was first observed.